Current state and upcoming opportunities for immunoPET biomarkers in lung cancer

Maarten Slebe; Johanna E. E. Pouw; Sayed M. S. Hashemi; C. Willemien Menke-van der Houven van Oordt; Maqsood M. Yaqub; Idris Bahce

doi:https://doi.org/10.1016/j.lungcan.2022.05.017

Current state and upcoming opportunities for immunoPET biomarkers in lung cancer

Maarten Slebe, Johanna E. E. Pouw, Sayed M. S. Hashemi, C. Willemien Menke-van der Houven van Oordt, Maqsood M. Yaqub, Idris Bahce

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

Immune oncology therapy (IO) has now become an important treatment option for patients with a non-small cell lung cancer (NSCLC). However, a substantial proportion of patients still fails to benefit from IO. Predictive biomarkers and biomarkers that provide insights in the biological processes at the tumor microenvironment (TME) level could enhance the beneficial impact of IO, and lead to improved drug development strategies. Immune positron emission tomography (immunoPET) has the potential to provide such biomarkers, by using highly-specific, radiolabeled tracers to investigate key targets in the TME with PET imaging. This review will highlight developments in immunoPET biomarkers, and the corresponding tracers and radionuclides used in cancer, and more specifically NSCLC. We will focus on available clinical tracers as well as those under development, providing an overview of each TME target, and the available clinical validation. Recent advances that could improve immunoPET in the upcoming years will be discussed.

Original language	English
Pages (from-to)	84-93
Number of pages	10
Journal	Lung Cancer
Volume	169
Early online date	31 May 2022
DOIs	https://doi.org/10.1016/j.lungcan.2022.05.017 https://doi.org/10.1016/j.lungcan.2022.05.017
Publication status	Published - Jul 2022

Keywords

Biomarkers
Immune oncology
NSCLC
immunoPET

Access to Document

Cite this

@article{221a41c23efc4e45accc8bcb8244b9e0,

title = "Current state and upcoming opportunities for immunoPET biomarkers in lung cancer",

abstract = "Immune oncology therapy (IO) has now become an important treatment option for patients with a non-small cell lung cancer (NSCLC). However, a substantial proportion of patients still fails to benefit from IO. Predictive biomarkers and biomarkers that provide insights in the biological processes at the tumor microenvironment (TME) level could enhance the beneficial impact of IO, and lead to improved drug development strategies. Immune positron emission tomography (immunoPET) has the potential to provide such biomarkers, by using highly-specific, radiolabeled tracers to investigate key targets in the TME with PET imaging. This review will highlight developments in immunoPET biomarkers, and the corresponding tracers and radionuclides used in cancer, and more specifically NSCLC. We will focus on available clinical tracers as well as those under development, providing an overview of each TME target, and the available clinical validation. Recent advances that could improve immunoPET in the upcoming years will be discussed.",

keywords = "Biomarkers, Immune oncology, NSCLC, immunoPET",

author = "Maarten Slebe and Pouw, {Johanna E. E.} and Hashemi, {Sayed M. S.} and {van Oordt}, {C. Willemien Menke-van der Houven} and Yaqub, {Maqsood M.} and Idris Bahce",

year = "2022",

month = jul,

doi = "https://doi.org/10.1016/j.lungcan.2022.05.017",

language = "English",

volume = "169",

pages = "84--93",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Current state and upcoming opportunities for immunoPET biomarkers in lung cancer

AU - Slebe, Maarten

AU - Pouw, Johanna E. E.

AU - Hashemi, Sayed M. S.

AU - van Oordt, C. Willemien Menke-van der Houven

AU - Yaqub, Maqsood M.

AU - Bahce, Idris

PY - 2022/7

Y1 - 2022/7

N2 - Immune oncology therapy (IO) has now become an important treatment option for patients with a non-small cell lung cancer (NSCLC). However, a substantial proportion of patients still fails to benefit from IO. Predictive biomarkers and biomarkers that provide insights in the biological processes at the tumor microenvironment (TME) level could enhance the beneficial impact of IO, and lead to improved drug development strategies. Immune positron emission tomography (immunoPET) has the potential to provide such biomarkers, by using highly-specific, radiolabeled tracers to investigate key targets in the TME with PET imaging. This review will highlight developments in immunoPET biomarkers, and the corresponding tracers and radionuclides used in cancer, and more specifically NSCLC. We will focus on available clinical tracers as well as those under development, providing an overview of each TME target, and the available clinical validation. Recent advances that could improve immunoPET in the upcoming years will be discussed.

AB - Immune oncology therapy (IO) has now become an important treatment option for patients with a non-small cell lung cancer (NSCLC). However, a substantial proportion of patients still fails to benefit from IO. Predictive biomarkers and biomarkers that provide insights in the biological processes at the tumor microenvironment (TME) level could enhance the beneficial impact of IO, and lead to improved drug development strategies. Immune positron emission tomography (immunoPET) has the potential to provide such biomarkers, by using highly-specific, radiolabeled tracers to investigate key targets in the TME with PET imaging. This review will highlight developments in immunoPET biomarkers, and the corresponding tracers and radionuclides used in cancer, and more specifically NSCLC. We will focus on available clinical tracers as well as those under development, providing an overview of each TME target, and the available clinical validation. Recent advances that could improve immunoPET in the upcoming years will be discussed.

KW - Biomarkers

KW - Immune oncology

KW - NSCLC

KW - immunoPET

UR - http://www.scopus.com/inward/record.url?scp=85131573302&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.lungcan.2022.05.017

DO - https://doi.org/10.1016/j.lungcan.2022.05.017

M3 - Review article

C2 - 35679715

SN - 0169-5002

VL - 169

SP - 84

EP - 93

JO - Lung Cancer

JF - Lung Cancer

ER -

Current state and upcoming opportunities for immunoPET biomarkers in lung cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this